David Mahvi to Treatment Outcome
This is a "connection" page, showing publications David Mahvi has written about Treatment Outcome.
Connection Strength
0.210
-
Minimally invasive therapies for hepatic malignancy. Curr Probl Surg. 2013 Apr; 50(4):146-79.
Score: 0.047
-
Education and Imaging. Hepatobiliary and pancreatic: anomalous pancreaticobiliary junction and gallbladder cancer. J Gastroenterol Hepatol. 2012 Oct; 27(10):1644.
Score: 0.046
-
Defining, controlling, and treating a pancreatic fistula. J Gastrointest Surg. 2009 Jul; 13(7):1187-8.
Score: 0.036
-
A prospective study of laparoscopic spinal fusion. Technique and operative complications. Ann Surg. 1996 Jul; 224(1):85-90.
Score: 0.015
-
ERCP in potentially resectable malignant biliary obstruction is frequently unsuccessful when performed outside of a comprehensive pancreaticobiliary center. J Surg Oncol. 2016 May; 113(6):647-51.
Score: 0.014
-
Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Ann Surg Oncol. 2010 Feb; 17(2):371-6.
Score: 0.009
-
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008 Aug; 248(2):273-9.
Score: 0.009
-
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.
Score: 0.007
-
Bowel obstruction in patients with metastatic cancer: does intervention influence outcome? Int J Gastrointest Cancer. 2005; 35(2):127-33.
Score: 0.007
-
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15; 22(22):4463-73.
Score: 0.007
-
Minimally invasive approaches in management of hepatic tumors. Surg Technol Int. 2003; 11:144-53.
Score: 0.006
-
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997 Dec 03; 89(23):1789-96.
Score: 0.004
-
Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers. Anal Quant Cytol Histol. 1997 Aug; 19(4):316-28.
Score: 0.004